---
title: "Liminatus Pharma regains Nasdaq compliance"
url: "https://aibio.space/news/liminatus-pharma-regains-nasdaq-compliance-after-1-50-reverse-split/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-09-29"
section: "Listings"
tickers: "NASDAQ:LIMN"
source: "https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/tm2626488d1_ex99-1.htm"
summary: "Nasdaq told the company on September 24, 2026 that its shares had closed above $1.00 for 13 straight trading days, closing the matter."
---

By the aibio.space news desk.

Sources

- [Liminatus Pharma, Inc. 8-K (2026-09-29)](https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/tm2626488d1_ex99-1.htm)

[LIMN](https://aibio.space/companies/liminatus-pharma/)

2026-09-29

# Liminatus Pharma regains Nasdaq compliance after 1-for-50 reverse split

Tickers [LIMN](https://aibio.space/companies/liminatus-pharma/)

Nasdaq told the company on September 24, 2026 that its shares had closed above $1.00 for 13 straight trading days, closing the matter.

## Key facts

- **Company**: Liminatus Pharma, Inc. (NASDAQ: LIMN)

- **News type**: Listings

- **Primary source**: [Liminatus Pharma, Inc. 8-K (2026-09-29)](https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/tm2626488d1_ex99-1.htm)

*The Washington Monument and the city beyond. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Liminatus Pharma, Inc. (Nasdaq: [LIMN](https://aibio.space/companies/liminatus-pharma/)) said it has regained compliance with Nasdaq's minimum bid price rule, which requires a listed stock to close at $1.00 or more.

The trouble began on January 15, 2026, when Nasdaq told the company its closing bid price had been below $1.00 for 30 consecutive business days. That put Liminatus out of line with Nasdaq Listing Rule 5450(a)(1), the bid price standard for The Nasdaq Global Market.

After an appeal and a hearing, the Nasdaq Hearings Panel moved the company to The Nasdaq Capital Market effective August 4, 2026. The Panel gave it until September 3, 2026 to meet Listing Rule 5550(a)(2), the Capital Market's bid price rule.

Liminatus then carried out a 1-for-50 reverse stock split at the close of trading on August 20, 2026. A reverse split combines existing shares into fewer shares, which raises the price of each one.

On September 24, 2026, Nasdaq notified the company that its closing bid price had been above $1.00 for the 13 consecutive trading days from August 21, 2026 to September 9, 2026. Nasdaq said the matter "is now closed," according to the company's [press release](https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/tm2626488d1_ex99-1.htm).

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

LIMN

Liminatus Pharma, Inc.

NASDAQ · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/liminatus-pharma-regains-nasdaq-compliance-after-1-50-reverse-split/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Liminatus Pharma regains Nasdaq compliance", 2026-09-29, https://aibio.space/news/liminatus-pharma-regains-nasdaq-compliance-after-1-50-reverse-split/